Diagnostics Lag Is Holding Back New Therapies, Says Study

Why It Matters

Without timely, affordable diagnostics, even the most innovative drugs cannot achieve their full clinical and commercial potential, slowing progress against major diseases and inflating healthcare costs.

Key Takeaways

• Therapeutics outpace diagnostics due to policy and payment gaps
• 47% of global population lacks adequate diagnostic access
• GLP‑1 drug response lacks predictive tests despite genetic insights
• Alzheimer’s blood tests are costly and rarely reimbursed
• Researchers urge joint regulatory review of drugs and diagnostics

Pulse Analysis

The rapid expansion of precision therapeutics has outstripped the growth of companion diagnostics, creating a systemic imbalance that threatens to stall medical innovation. Investment in drug development consistently eclipses funding for diagnostic tools, while insurers often reimburse tests at lower rates than treatments. This disparity discourages manufacturers from pursuing diagnostic research, leaving clinicians without the data needed to match patients to the right therapy. As a result, the promise of personalized medicine remains unevenly realized across markets, especially in low‑ and middle‑income regions where nearly half of the population lacks reliable testing infrastructure.

Concrete cases illustrate the stakes. GLP‑1 agonists, now frontline agents for obesity and type‑2 diabetes, show variable efficacy, yet predictive genetic or biomarker tests are scarce, forcing physicians to rely on trial‑and‑error prescribing. In Alzheimer’s disease, newly approved blood assays can identify candidates for disease‑modifying drugs such as lecanemab and donanemab, but their high price tags and limited insurance coverage mean many patients are treated without crucial diagnostic confirmation. These gaps not only diminish therapeutic outcomes but also inflate overall healthcare spending as ineffective treatments are administered.

Policymakers and regulators are urged to close the loop between drug and diagnostic pathways. Proposals include joint FDA review tracks, harmonized reimbursement frameworks, and incentives that reward co‑development of tests and therapies. Aligning incentives could accelerate the rollout of companion diagnostics, improve patient stratification, and unlock the full value of next‑generation medicines. For industry stakeholders, embracing an integrated approach may reduce time‑to‑market, expand market access, and ultimately drive better health outcomes worldwide.